Why Did Hikma Pharmaceuticals plc Shares Rise on 13 November 2026?

Hikma Pharmaceuticals plc (LSE:HIK) shares rose 0.18% to 1,653p on 13 November 2026. The pharmaceutical group remained in focus after publishing interim results for the six months ended 30 June 2026 on 6 August 2026.

The update reported core operating profit growth, higher Operating Cash Flow and a reiterated full-year outlook.

Key Highlights

Group Revenue rose 4% to $1,728m and core operating profit rose 9% to $405m, with the core Operating Margin at 23.4%. Core EBITDA increased 8% to $463m.

Operating cash flow was $214m, up 33%, and the ratio of net Debt to core EBITDA was 1.9x. The Interim Dividend increased 6% to 38 cents per share, and a $250m share buyback programme continues.

About Hikma Pharmaceuticals plc

Hikma is a multinational pharmaceutical company with three businesses: Injectables, Branded and Hikma Rx, which is its US generics operation. It serves patients in the US, the Middle East and North Africa, and Europe.

The group is known for its broad range of injectable medicines used in hospitals.

Branded Business

Branded revenue rose 15% to $502m, and core operating profit rose 23%, with the core operating margin at 32.5%. The Branded Business serves markets across the Middle East and North Africa and carries the group's highest margin.

Growth in this division changes the overall mix of the group, which is one reason investors follow its progress closely.

Hikma Rx and Injectables

Hikma Rx revenue was $520m, broadly flat, while core operating profit grew 16% and the core operating margin was 20.6%. Injectables revenue was $685m.

Management noted that Injectables revenue and profit are weighted to the second half of the year, with full-year margin guidance of 27% to 28%.

Guidance

The group reiterated full-year 2026 guidance for revenue growth of 2% to 4% in constant currency and core operating profit of $720m to $770m. The 2025 core operating profit was $741m on revenue of $3,349m.

Reiterating guidance at the interim stage gives investors a clear reference for the second half.

Capital Returns and Balance Sheet

The interim dividend of 38 cents per share represents a 6% increase. The ongoing $250m buyback programme is a further form of Capital return alongside Investment in the business.

A net debt to core EBITDA ratio of 1.9x shows how borrowings compare with earnings, and it is a common measure of Balance Sheet capacity.

Understanding Core Operating Profit

Core operating profit excludes certain items that management treats as non-core, such as legal settlements and acquisition-related costs. It is designed to show underlying performance and is the main measure behind the group's guidance.

Reported figures include all items and can therefore differ from core figures in a given period.

Why the Update Matters for the Sector

Pharmaceutical groups with a mix of injectables, branded and generic products are followed for how each division contributes to margin. Hikma's results show growth in the higher-margin Branded business alongside steady performance elsewhere.

The geographic spread across the US and MENA regions also gives investors a view of how Demand in different healthcare systems is evolving.

Reading the Segment Mix

Hikma reports through three segments, and each carries a different margin profile and seasonality. Following them separately helps investors understand how group results are built over the year.

Key Growth Catalysts

Branded growth, new product launches and margin improvement in Hikma Rx provide routes for further progress. The second-half weighting in Injectables is an expected feature of the year.

Factors to Monitor

Pricing in generics, regulatory approvals and currency movements can influence results. Timing of launches also affects the split between halves.

What Investors Should Watch Next

Investors may wish to follow second-half Injectables delivery, Branded growth, cash generation, buyback progress and any guidance updates.

Conclusion

Hikma Pharmaceuticals plc (LSE:HIK) rose 0.18% to 1,653p on 13 November 2026. Hikma reported 9% growth in core operating profit, higher cash flow and a 6% higher interim dividend, and it reiterated full-year guidance. Second-half delivery is the main item to follow.